| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 308,460 | 391,292 | ||
| Accounts receivable, net | 2,099,065 | 1,860,715 | ||
| Inventory note 3 | 2,256,289 | 1,783,426 | ||
| Deposits and other receivables | 872,420 | 1,109,107 | ||
| Total current assets | 5,536,234 | 5,144,540 | ||
| Deposits and other receivables note 12 | 109,297 | 109,297 | ||
| Long-term accounts receivable | 83,939 | 74,188 | ||
| Property and equipment note 13 | 6,622 | 8,111 | ||
| Operating right of use assets note 12 | 586,680 | 701,183 | ||
| Total assets | 6,322,772 | 6,037,319 | ||
| Accounts payable and accrued liabilities note 4 | 7,908,201 | 7,856,775 | ||
| Convertible promissory notes and short term loans note 5 | 10,394,614 | 10,084,601 | ||
| Term loan, current | 2,400,000 | 2,400,000 | ||
| Derivative liabilities note 8 | 443,583 | 438,162 | ||
| Advance from customers | 1,895,920 | 475,575 | ||
| Operating lease obligations, current note 10 | 571,706 | 551,208 | ||
| Total current liabilities | 23,614,024 | 21,806,321 | ||
| Federally guaranteed loans note 7 | 870,800 | 870,800 | ||
| Term loan note 6 | 12,015,626 | 12,425,131 | ||
| Derivative liabilities note 8 | 1,382,103 | 1,481,522 | ||
| Operating lease obligations | 102,307 | 252,172 | ||
| Total liabilities | 37,984,860 | 36,835,946 | ||
| Series b convertible redeemable preferred stock, 0.001 par value, 600 shares authorized as of september 30, 2025 and march 31, 2025, respectively, 360 and 385 shares issued and outstanding as of september 30, 2025 and march 31, 2025, respectively note 9-Series BConvertible Redeemable Preferred Stock | 1,750,290 | 2,000,290 | ||
| Series a preferred stock, 0.001 par value, 20,000 shares authorized as at september 30, 2025 and march 31, 2025, respectively, 201 and 201 shares issued and outstanding as at september 30, 2025 and as at march 31, 2025, respectively note 9 | 1 | 1 | ||
| Common stock, 0.001 par value, 125,000,000 shares authorized as at september 30, 2025 and march 31, 2025, respectively. issued and outstanding common shares 26,791,608 and 26,081,295 as at september 30, 2025 and march 31, 2025, respectively, and exchangeable shares of 160,672 outstanding as at september 30, 2025 and march 31, 2025, respectively note 9 | 26,953 | 26,729 | ||
| Shares to be issued 581,599 and 324,276 shares of common stock as at september 30, 2025 and march 31, 2025, respectively note 9 | 284,244 | 284,244 | ||
| Additional paid-in-capital | 107,278,101 | 106,976,564 | ||
| Accumulated other comprehensive loss | -33,276 | 109,623 | ||
| Accumulated deficit | -140,968,401 | -140,196,078 | ||
| Total stockholders equity (deficiency) | -33,412,378 | -32,798,917 | ||
| Total liabilities, mezzanine and stockholders deficiency | 6,322,772 | 6,037,319 | ||
BIOTRICITY INC. (BTCY)
BIOTRICITY INC. (BTCY)